Page 6 - APN July 2017

Zoetis Fostera PCV MH.
The Zoetis pig team.
The Q&A session provided a great opportunity for those in attendance to quiz the Zoetis team.
Be sure
Dehydration prevention
Vet Only Ez-Lyte
• Green apple flavoured electrolyte and acidifier
• Easy to use solution
• Improves water intake of weaners
• Can be administered directly by a 1:50 doser
• Aids digestion in weaners
To find out more contact
Page 6 – Australian Pork Newspaper, July 2017
www.porknews.com.au
Zoetis launches new bivalent vaccine
ONJune28and29at the PARKROYAL Mel- bourne Airport, Zoetis held the Australian tech- nical launch of Fostera PCV MH, a new from the ground up vaccine designed to provide pigs with protection against both porcine circovirus type 2 and mycoplasma hyopneumoniae.
Fostera PCV MH is uniquely developed to balance antigen levels and target the animal’s immune response, with one bottle containing the ready-to-use vaccine with flexible dosing options.
These dosing options are to either inject 2ml intra- muscularly into pigs three weeks of age or older, or inject two 1ml doses at a two-week interval from three weeks of age or older.
Fostera PCV MH is a true combined bivalent vaccine, not a mix of two existing products, with aspects of human vac- cine technology applied to the manufacturing process that sees science combined with innova- tion to create an effective formulation against two diseases.
The manufacturing pro- cess also helps remove ex- traneous proteins that can affect efficacy and safety, with the PCV2 antigen concentrated and diafil- trated and the M. hyo an- tigen filtered and treated with protein A to help re- duce anti-PCV2 and other antibodies, resulting in better compatibility with the PCV2 antigen.
Additionally, the Zoetis MetaStim adjuvant helps induce an effective im- mune response within the pig.
Through extensive safety and efficacy trials, it was found that Fos- tera PCV MH, whether administered using the two-dose or single-dose options, aids in the con- trol of PCVAD, while the presence of M. hyo in the formulation does not interfere with PCV2 efficacy.
Both dosing regimens aided in the control of en- zootic pneumonia caused by M. hyo, with the pres- ence of PCV2 in the for- mulation not interfering with M. hyo efficacy.
Furthermore, both dos- ing options were deemed safe to administer from weaning age, and through testing only a low inci-
dence of mild, quick-re- solving injection site reac- tions were observed.
During comparative testing of one and two- dose PCV2 and M. hyo vaccine combinations (mixed monovalent and bivalent) following dual challenge with PCV2 and M. hyo, Fostera PCV MH (one and two-dose) dem- onstrated efficacy against the PCV2 challenge as demonstrated by virae- mia, shedding, histopa- thology and colonisation.
Both dosing options of Fostera PCV MH also demonstrated efficacy against the M. hyo chal- lenge as demonstrated by LS mean lung lesions.
Overall, Fostera PCV MH saw a 91.3 percent re- duction in viraemic pigs, a 70 percent reduction in faecal shedding, a 91- 100 percent reduction in PCV2 lymphoid lesions, 77.4 percent less PCV2 antigen in lymphoid tis- sues and a 76.3 percent reduction in M. hyo lung lesions compared to con- trols.
Available in two bottle
sizes of 100ml and 500ml to suit pig farms large and small, the addition- al convenience afforded by a single-dose vaccine to combat two diseases makes Fostera PCV MH the logical choice in to- day’s busy farming opera- tions.
Offering at least the same protection against PCV2 and M. hyo as you would expect from
monovalent vaccines, the ready-to-use Fostera PCV MH vaccine is safe, ef- ficacious and convenient.
Zoetis Fostera PCV MH is expected to land in Aus- tralia in early August.
For more information, contact your veterinarian or local Zoetis representa- tive.
You can call Zoetis on 1800 963 847 or visit zoe tis.com.au/fostera
US veterinarian Brian Payne of Pipestone Veterinary Services flew in to give an insight into transmission of disease in the sow heard.
NEW
API18393